Azithromycin News and Research

RSS

Azithromycin, also known as Zithromax, belongs to the class of medicines known as antibacterials orantibiotics. These medicines kill bacteria (small organisms that can cause infection in humans) or stopbacteria from growing. Patients with weakened immune systems, includingpeople with HIV, tend to have more frequent andmore serious bacterial infections. Azithromycinwas approved by the FDA on June 14, 1996, formany uses, including the prevention and treatmentof Mycobacterium avium complex (MAC) inpersons with advanced HIV infection. It is alsobeing investigated to see how well it works inpreventing other kinds of bacterial infections inpeople with HIV.

Meta-analysis confirms complete failure of hydroxychloroquine/chloroquine as a COVID-19 treatment

Researchers investigate the efficacy of hydroxychloroquine and chloroquine in the treatment of patients hospitalized with COVID-19.

17 Jan 2022

Researchers find a digital silver lining in failed COVID-19 drug trial

A clinical trial in which two test drugs failed to help patients with mild COVID-19 nevertheless had a silver lining: It proved the viability of a study model in which a medication's potential arrhythmic side effects are safely, effectively monitored without the participants ever setting foot in a hospital or clinic.

20 Dec 2021

Hyperbaric oxygen treatment quickly resolves severe breathing difficulties in COVID-19 patients

High pressure (hyperbaric) oxygen resolves severe breathing difficulties in COVID-19 patients much more quickly than standard therapy, taking an average of 3 rather than 9 days, reveal the results of a small comparative clinical trial published online in Emergency Medicine Journal.

15 Dec 2021

Screening FDA-approved compounds shown to possess antiviral or antimicrobial activity for SARS-CoV-2 inhibition

Researchers have screened several compounds that could show the ability to inhibit SARS-CoV-2.

10 Dec 2021

Current understanding of the link between COVID-19 and cardiovascular disease

A review published in Chemo-Biological Interactions has focused on the prevalence of COVID-19 in CVD patients associated with ACE2 mechanisms.

10 Nov 2021

Automated method shows predictive power for COVID-19 in-hospital mortality

Researchers focussed on the S-learner strategy of estimating the conditional average treatment effect.

4 Nov 2021

Scientists suggest a new approach to mitigating the collateral damage from antibiotics

Antibiotics help us to treat bacterial infections and save millions of lives each year. But they can also harm the helpful microbes residing in our gut, weakening one of our body's first lines of defense against pathogens and compromising the multiple beneficial effects our microbiota has for our health.

13 Oct 2021

Antibiotics alone cannot prevent stunted growth in children, study finds

Antibiotics alone likely cannot overcome the complex factors that cause stunted growth and perpetuate the cycle of poverty in the developing world, new research suggests.

8 Oct 2021

Dispensing of hydroxychloroquine and ivermectin in Australia jumped in first year of COVID

A new study describes the nature and extent of the shift in dispensing these medications, as well as its eventual outcome.

3 Oct 2021

Effect of biologic therapy on COVID-19 in children suffering from rheumatic diseases

A new study aimed to determine the course of SARS-CoV-2 infection in children suffering from rheumatic disease and were receiving bDMARD treatment.

29 Sep 2021

Potential covalent SARS-CoV-2 spike protein inhibitors

There remains a significant need for new and effective drugs that can be used to treat COVID-19.

23 Sep 2021

Consumption of common antibiotic during pregnancy can reduce low birth weight and premature births

A common antibiotic has been found to reduce low birth weight and premature births, if taken during pregnancy, in countries where malaria is endemic, according to a research review.

22 Sep 2021

COVID-19 associated mucormycosis cases in India

India continues to grapple with the coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, the country has reported over one million new cases for the past 28 days.

31 Aug 2021

Study demonstrates the potency of herbal medicines against Bartonella henselae

Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced the publication of new data showing that herbal medicines have potent activity in test tubes compared to pharmaceuticals commonly-prescribed for the treatment of Bartonella henselae, a bacterium believed to be carried by ticks and the cause of cat scratch fever.

5 Aug 2021

COVID-19 first wave increased the sale of antibiotic formulations in India

The first wave of COVID-19 in 2020 in India saw a substantial increase in the sale of antibiotic formulations used in adults and adolescents, especially azithromycin, says a study.

19 Jul 2021

Broad-spectrum antibiotic no more effective than placebo in preventing COVID-19 symptoms

A UC San Francisco study has found that the antibiotic azithromycin was no more effective than a placebo in preventing symptoms of COVID-19 among non-hospitalized patients, and may increase their chance of hospitalization, despite widespread prescription of the antibiotic for the disease.

16 Jul 2021

What lessons have we learned over a year into the COVID-19 pandemic?

One of the pressing questions scientists are currently trying to answer is whether the current vaccines will remain effective against the emerging SARS-CoV-2 variants of concern. A new piece of research has been published in the journal Biomedicines, which discusses the knowledge we have gained thus far and the questions that researchers should address in future work.

8 Jun 2021

The great promise of antiviral peptides against SARS-CoV-2

A new study, recently published in the journal Viruses, describes the impressive evidence for the role of antimicrobial peptidse (AMPs) in the treatment of COVID-19.

7 Jun 2021

Hydroxychloroquine + Azithromycin therapy at a higher dose improved survival by nearly 200% in ventilated COVID patients

However, a fascinating new study posted to the medRxiv* preprint server suggests that such disappointment may have been both premature and unwarranted, based on a re-analysis of over 250 patients on invasive mechanical ventilation (IMV) during the first two months of the pandemic.

2 Jun 2021

Are COVID-19 medications safe in pregnancy?

Most medications being tested today in clinical trials for the treatment of coronavirus disease 2019 (COVID-19) have been repurposed from other indications. These are typically not tested in pregnant women. A new study, published in the journal PLOS ONE, summarizes what is known about the safety of these drugs in this group.

24 May 2021